The Manufacturers Life Insurance Company acquired a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,910 shares of the medical instruments supplier’s stock, valued at approximately $1,047,000.
Several other large investors have also recently bought and sold shares of LMAT. Sound Income Strategies LLC raised its holdings in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares during the period. Catalyst Capital Advisors LLC acquired a new position in shares of LeMaitre Vascular in the 1st quarter valued at $32,000. Geneos Wealth Management Inc. grew its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares during the period. EverSource Wealth Advisors LLC bought a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at $47,000. Finally, Quarry LP increased its position in shares of LeMaitre Vascular by 267.2% in the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after buying an additional 529 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.
Analysts Set New Price Targets
Several research firms have weighed in on LMAT. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 14th. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $110.60.
LeMaitre Vascular Stock Up 0.2%
LeMaitre Vascular stock opened at $80.67 on Friday. The company’s 50-day moving average price is $91.88 and its two-hundred day moving average price is $99.10. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The stock has a market cap of $1.84 billion, a P/E ratio of 28.31, a P/E/G ratio of 2.32 and a beta of 0.50. LeMaitre Vascular, Inc. has a twelve month low of $78.27 and a twelve month high of $118.01.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The firm had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The company’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.60 EPS. As a group, analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.
LeMaitre Vascular Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th were given a dividend of $0.25 per share. The ex-dividend date was Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 35.09%.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Featured Articles
- Five stocks we like better than LeMaitre Vascular
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
